

## Claudin-3 (D7A3O) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

<b>Applications:</b> W, IP, IF-IC	Reactivity: H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 20	<b>Source/Isotype:</b> Rabbit IgG	<b>UniProt ID:</b> #O15551	Entrez-Gene Id: 1365
Product Usage Information	<b>e</b>	<b>Application</b> Western Blotting Immunoprecipitation Immunofluorescence		nistry)		<b>Dilution</b> 1:1000 1:200 1:200
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		Claudin-3 (D7A3O) Rabbit mAb recognizes endogenous levels of total claudin-3 protein.				
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro206 of human claudin-3 protein.				
Background		Tight junctions, or zonula occludens, form a continuous barrier to fluids across the epithelium and endothelium. They function in regulation of paracellular permeability and in the maintenance of cell polarity, blocking the movement of transmembrane proteins between the apical and the basolateral cell surfaces. Tight junctions are composed of claudin and occludin proteins, which join the junctions to the cytoskeleton (1,2). The claudin family is composed of 23 integral membrane proteins, and their expression, which varies among tissue types, may determine both the strength and properties of the epithelial barrier. Alteration in claudin protein expression pattern is associated with several types of cancer (2,3). Claudin-1 is expressed primarily in keratinocytes (4) and normal mammary epithelial cells, but is absent or reduced in breast carcinomas and breast cancer cell lines (5,6).  Claudin-3 is the product of an intronless gene ( <i>CLDN3</i> ) whose expression is markedly dysregulated in distinct cancer subtypes, including ovarian and breast carcinomas (7-9). Somewhat paradoxically, reduced claudin-3 expression is also a hallmark of a subset of breast tumors known as the claudin-low subtype, in which reduced claudin-3 expression was shown to correlate with a phenotype characteristic of cells undergoing epithelial-mesenchymal transition (10).				
Background References		<ol> <li>Shin, K. et al. (2006) Annu Rev Cell Dev Biol 22, 207-35.</li> <li>Oliveira, S.S. and Morgado-Díaz, J.A. (2007) Cell Mol Life Sci 64, 17-28.</li> <li>Hewitt, K.J. et al. (2006) BMC Cancer 6, 186.</li> <li>Brandner, J.M. et al. (2002) Eur J Cell Biol 81, 253-63.</li> <li>Krämer, F. et al. (2000) Hum Genet 107, 249-56.</li> <li>Swisshelm, K. et al. (1999) Gene 226, 285-95.</li> <li>Choi, Y.L. et al. (2007) Histol Histopathol 22, 1185-95.</li> <li>Hudson, L.G. et al. (2008) Clin Exp Metastasis 25, 643-55.</li> <li>Todd, M.C. et al. (2015) Oncol Lett 10, 156-162.</li> <li>Herschkowitz, J.I. et al. (2012) Proc Natl Acad Sci U S A 109, 2778-83.</li> </ol>				
Species Reacti	vity	Species reactivity is de	etermined by testir	ng in at least one approve	ed application (e.g.,	western blot).
Mark Black		IMPORTANT 5	and black to the total	and the second second second		- F0//. BCA 43/

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at  $4^{\circ}$ C with gentle shaking, overnight.

**Applications Key** 

**W**: Western Blotting **IP**: Immunoprecipitation **IF-IC**: Immunofluorescence (Immunocytochemistry)

**Cross-Reactivity Key** 

**H:** Human

**Trademarks and Patents** 

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

XP is a registered trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

## **Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party. whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.